TELA Bio (TELA) Asset Writedowns and Impairment (2018 - 2026)

TELA Bio's Asset Writedowns and Impairment history runs 9 years deep, the most recent figure standing at $935000.0 for Q1 2026.

• In Q1 2026, Asset Writedowns and Impairment rose 48.41% year-over-year to $935000.0; the TTM figure through Mar 2026 stood at $2.7 million (down 11.9% YoY), while the FY2025 annual figure was $2.4 million, down 20.14% from the prior year.
• Asset Writedowns and Impairment was $935000.0 for Q1 2026 at TELA Bio, up from $818000.0 in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $1.4 million in Q4 2024 to a low of $57000.0 in Q4 2022.
• Historically, Asset Writedowns and Impairment has averaged $560588.2 across 5 years, with a median of $576000.0 in 2023.
• Biggest YoY gain for Asset Writedowns and Impairment was 640.35% in 2023; the steepest drop was 63.22% in 2023.
• A 5-year view of Asset Writedowns and Impairment shows it stood at $57000.0 in 2022, then surged by 640.35% to $422000.0 in 2023, then surged by 229.86% to $1.4 million in 2024, then tumbled by 41.24% to $818000.0 in 2025, then rose by 14.3% to $935000.0 in 2026.
• The last three Asset Writedowns and Impairment figures came in at $935000.0 (Q1 2026), $818000.0 (Q4 2025), and $632000.0 (Q3 2025), per Business Quant data.